CSIMarket


Aslan Pharmaceuticals Limited  (ASLN)
Other Ticker:  
 


 

Aslan Pharmaceuticals Limited

ASLN's Financial Statements and Analysis



Aslan Pharmaceuticals Limited increased forth quarter of 2022 net loss per share of $-0.15 compare to net loss per share of $-0.10 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


forth quarter of 2022
Earnings Per Share Revenues
$ -0.15 $  0 Mill
$-0.05     Unch.    



Aslan Pharmaceuticals Limited's Revenue fell by 0 % in forth quarter of 2022 (Dec 31 2022) year on year, to $0 million and declined by sequentially.


Aslan Pharmaceuticals Limited is

More on ASLN's Income Statement



Aslan Pharmaceuticals Limited's in theforth quarter of 2022 recorded net loss of $-51.382 million, an increase from net loss of $-31.591 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.000 million in the previous quarter.

More on ASLN's Growth

Aslan Pharmaceuticals Limited Inventories
ASLN's Cash flow In the forth quarter of 2022 company's net cash flow was $90 million, capital expenditures grew by -0.036448-25.62%, to $0 millions compare to same quarter a year ago

More on ASLN's Cash flow Statement


Aslan Pharmaceuticals Limited does not pay out common stock dividend.

In trailing twelve-month period Aslan Pharmaceuticals Limited payed $ -0.22 cash per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $0.02 per share.
Tangible Book value fell to $ 0.02 per share from $ 0.02.

Company repurchased 0.00 million shares or 0.00 % in Dec 31 2022.


More on ASLN's Dividends

 Market Capitalization (Millions) 218
 Shares Outstanding (Millions) 343
 Total Debt (Millions $) 30
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Aslan Pharmaceuticals Limited does not pay out common stock dividend.

In trailing twelve-month period Aslan Pharmaceuticals Limited had negative $ -0.22 cash flow per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $0.02 per share.
Tangible Book value fell to $ 0.02 per share from $ 0.02.

Company repurchased 0.00 million shares or 0.00 % in Dec 31 2022.


More on ASLN's Balance Sheets

 Market Capitalization (Millions) 218
 Shares Outstanding (Millions) 343
 Total Debt (Millions $) 30
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -51
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   



Date modified: 2023-03-26T05:28:45+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com